Benzinga | Nov 18, 2020 11:03AM EST

Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Raises Price Target to $110

Canaccord Genuity maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and raises the price target from $108 to $110.